This Key Event Relationship is licensed under the Creative Commons BY-SA license. This license allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.
Relationship: 3368
Title
Increased, cholesterol synthesis enzymes leads to Increased, plasma LDL cholesterol
Upstream event
Downstream event
Key Event Relationship Overview
AOPs Referencing Relationship
| AOP Name | Adjacency | Weight of Evidence | Quantitative Understanding | Point of Contact | Author Status | OECD Status |
|---|---|---|---|---|---|---|
| Activation, Pregnane-X receptor, NR1l2 leads to increased plasma low-density lipoprotein (LDL) cholesterol via increased cholesterol synthesis | adjacent | High | John Frisch (send email) | Under development: Not open for comment. Do not cite |
Taxonomic Applicability
| Term | Scientific Term | Evidence | Link |
|---|---|---|---|
| mammals | mammals | High | NCBI |
Sex Applicability
| Sex | Evidence |
|---|---|
| Unspecific | High |
Life Stage Applicability
| Term | Evidence |
|---|---|
| All life stages | Moderate |
Key Event Relationship Description

Cholesterol has a variety of roles in organisms, including as a cellular membrane component that helps maintain structure and fluidity, and a precursor for steroid hormones (Sakakura et al. 2001; Horton et al. 2003; Howe et al. 2017). The cholesterol synthesis pathway involves a number of precursor molecules and enzymes (Sakakura et al. 2001; Itkonen et al. 2023), with high cholesterol levels acting as a negative feedback on additional cholesterol synthesis (Itkonen et al. 2023; MacFarlaine et al. 2014). Individuals with high levels of plasma low-density lipoprotein (LDL) cholesterol have departed from lipid homeostasis in maintaining cholesterol levels needed for typical function, and in displaying hypercholesterolemia are at greater risk of cardiovascular events (Lalanne et al. 2005; Lambert et al. 2006).
Evidence Collection Strategy
This Key Event Relationship was developed as part of an Environmental Protection Agency effort to represent putative AOPs from peer-reviewed literature which were heretofore unrepresented in the AOP-Wiki. Itkonen et al. (2023) focused on identifying Adverse Outcome Pathways that linked PXR activation to increased level of plasma low-density lipoprotein (LDL) cholesterol through review of existing literature, and provided initial network analysis.
Cited empirical studies are focused on increased cholesterol synthesis enzymes and resulting increased plasma low-density lipoprotein (LDL) cholesterol levels in mammals, in support of development of AOP 545 for Itkonen et al. (2023) content.
Authors of KER 3368 did a further evaluation of published peer-reviewed literature to provide additional evidence in support of the key event relationship.
Evidence Supporting this KER
Biological Plausibility
Cholesterol synthesis enzymes and plasma low-density lipoprotein (LDL) cholesterol levels have been studied in a variety of gene-knockout, gene transfection, and diet studies designed to disrupt maintenance of lipid homeostasis in laboratory mammals. Evidence from gene expression and protein expression studies show a consistent response in increase in cholesterol synthesis enzyme expression and plasma low-density lipoprotein (LDL) cholesterol levels, which reinforces the evidence for the enzymes role in biosynthesis of cholesterol. Cholesterol levels can also also be affected by changes in diet, uptake, and elimination (Duan et al. 2022).
Empirical Evidence
|
Species |
Duration |
Dose |
Increased cholesterol synthesis enzymes? |
Increased plasma LDL cholesterol? |
Summary |
Citation |
|
Mouse (Mus musculus) |
2.5 days |
Gene knockout study, high fat 2.0 % cholesterol diet. |
yes |
yes |
Mice with knock-out INSIG regulator genes had increased gene and enzyme expression for loci involved in cholesterol synthesis versus wild-type mice (no statistical analysis), leading to statistically significant increased plasma cholesterol levels versus wild-type mice (type of cholesterol not measured but increased LDL is plausible). |
Engleking et al. (2005) |
|
Mouse (Mus musculus |
20 weeks |
Gene knockout study |
yes |
yes |
Mice with knock-out INSIG regulator genes had statistically significant increased gene expression for cholesterol synthesis enzymes and lipid synthesis activity, leading to statistically significant increased plasma cholesterol levels versus wild-type mice (type of cholesterol not measured but increased LDL is plausible). |
MacFarlaine et al. (2014) |
|
Mouse (Mus musculus) |
1 week |
100 mg/kg body weight efavirenz daily. |
yes |
yes |
8 week old C57BL/6 male mice exposed to efavirenz had statistically significant increased cholesterol biosynthesis enzyme squalene epoxidase (SQLE) gene expression and increased SQLE protein expression per immunoblot, leading to statistically significant increased cholesterol synthesis and statistically significant increased plasma LDL cholesterol levels versus control mice. |
Gwag et al. (2019) |
Uncertainties and Inconsistencies
Known modulating factors
Quantitative Understanding of the Linkage
Response-response Relationship
Time-scale
Known Feedforward/Feedback loops influencing this KER
Domain of Applicability
Life Stage: All life stages.
Sex: Applies to both males and females.
Taxonomic: Primarily studied in humans and laboratory rodents.
References
Duan, Y., Gong, K., Xu, S., Zhang, F., Meng, X., and Han, J. 2022. Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics. Signal Transduction and Targeted Therapy 7: 265.
Gwag, T., Meng, Z., Sui, Y., Helsley, R.N., Park, S.-H., Wang, S., Greenberg, R.N., and Zhou, C. 2019. Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis. Journal of Hepatology 70: 930–940.
Horton, J.D., Shah, N.A., Warrington, J.A., Anderson, N.N., Park, S.W., Brown, M.S., and Goldstein, J.L. 2003. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proceedings of the National Academy of Sciences 100(21): 12027–12032.
Howe, V., Sharpe, L.J., Prabhu, A.V., and Brown, A.J. 2017. New insights into cellular cholesterol acquisition: promoter analysis of human HMGCR and SQLE, two key control enzymes in cholesterol synthesis. Biochim Biophys Acta 1862: 647–657.
Itkonen, A., Hakkola, J., and Rysa, J. 2023. Adverse outcome pathway for pregnane X receptor‑induced hypercholesterolemia. Archives of Toxicology 97: 2861–2877.
Lalanne, F., Lambert, G., Amar, M.J.A., Chetiveaux, M., Zair, Y., Jarnoux, A.-L., Ouguerram, K., Friburg, J., Seidah, N.G., Brewer, Jr., H.B., Krempf, M., and Costet, P. 2005. Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells. Journal of Lipid Research 46: 1312–1319.
Lambert, G., Jarnoux, A.-J., Pineau, T., Pape, O., Chetiveaux, M., Laboisse, C., Krempf, M., and Costet, P. 2006. Fasting induces hyperlipidemia in mice overexpressing Proprotein Convertase Subtilisin Kexin Type 9: Lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor. Endocrinology 147(10): 4985–4995.
MacFarlaine, M.R., Liang, G., and Engelking, L.J. 2014. Insig proteins mediate feedback inhibition of cholesterol synthesis in the intestine. The Journal of Biological Chemistry 289(4): 2148-2156.
Sakakura, Y., Shimano, H., Sone, H., Takahashi, A., Inoue, N., Toyshima, H., Suzuki, S. and Yamada, N. 2001. Sterol regulatory element-binding proteins induce an entire pathway of cholesterol synthesis. Biochemical and Biophysical Research Communications 286: 176–183.
NOTE: Italics indicate edits from John Frisch October 2024.